InvestorsHub Logo
Followers 30
Posts 2777
Boards Moderated 3
Alias Born 10/24/2015

Re: None

Wednesday, 02/27/2019 5:13:50 PM

Wednesday, February 27, 2019 5:13:50 PM

Post# of 77
AACR: Development & characterization of a new oncolytic immunotherapy platform based on herpes simplex virus type 1 https://www.abstractsonline.com/pp8/#!/6812/presentation/2764

A Phase I trial of talimogene laherparepvec combined with neoadjuvant chemotherapy for non-metastatic triple negative breast cancer https://www.abstractsonline.com/pp8/#!/6812/presentation/9841
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent REPL News